Axa S.A. Decreases Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Axa S.A. decreased its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 10.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,168 shares of the biotechnology company’s stock after selling 3,258 shares during the quarter. Axa S.A.’s holdings in Ironwood Pharmaceuticals were worth $184,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. Norges Bank bought a new stake in shares of Ironwood Pharmaceuticals in the 4th quarter worth about $9,321,000. Old West Investment Management LLC lifted its holdings in shares of Ironwood Pharmaceuticals by 1.4% in the 4th quarter. Old West Investment Management LLC now owns 56,921 shares of the biotechnology company’s stock worth $651,000 after acquiring an additional 761 shares during the last quarter. 13D Management LLC lifted its holdings in shares of Ironwood Pharmaceuticals by 971.8% in the 4th quarter. 13D Management LLC now owns 367,649 shares of the biotechnology company’s stock worth $4,206,000 after acquiring an additional 333,348 shares during the last quarter. Hotchkis & Wiley Capital Management LLC lifted its holdings in shares of Ironwood Pharmaceuticals by 4.0% in the 4th quarter. Hotchkis & Wiley Capital Management LLC now owns 1,140,470 shares of the biotechnology company’s stock worth $13,047,000 after acquiring an additional 43,800 shares during the last quarter. Finally, Parkman Healthcare Partners LLC lifted its holdings in shares of Ironwood Pharmaceuticals by 20.7% in the 4th quarter. Parkman Healthcare Partners LLC now owns 120,652 shares of the biotechnology company’s stock worth $1,380,000 after acquiring an additional 20,652 shares during the last quarter.

Ironwood Pharmaceuticals Stock Performance

NASDAQ IRWD opened at $4.26 on Thursday. The company has a market capitalization of $666.81 million, a price-to-earnings ratio of -0.63 and a beta of 0.49. The company’s 50-day simple moving average is $4.91 and its two-hundred day simple moving average is $6.35. Ironwood Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $15.70.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, insider Minardo John sold 9,910 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $4.27, for a total transaction of $42,315.70. Following the transaction, the insider now owns 284,661 shares of the company’s stock, valued at approximately $1,215,502.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 12.90% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Capital One Financial lowered shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $12.00 to $4.00 in a report on Thursday, August 8th. StockNews.com upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, July 16th. Leerink Partners initiated coverage on shares of Ironwood Pharmaceuticals in a report on Monday, September 9th. They set a “market perform” rating and a $5.00 price objective for the company. Leerink Partnrs upgraded shares of Ironwood Pharmaceuticals to a “hold” rating in a report on Monday, September 9th. Finally, Wells Fargo & Company decreased their price objective on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.17.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.